Arthneeti

TTK Healthcare Share Price & Earnings Call Analysis

₹915.75+0.16% today
Market cap
₹1,294 Cr
P/E
17.82
ROE
6.30%
PEG
-0.34
Price to sales
1.40
Debt to equity
0.02
52W high / low
₹1,191 / ₹740
Sales growth (5Y)
12.48%
EBITDA margin
3.99%
Net profit margin
8.01%
Promoter holding
74.57%
Sales (last year)
₹918 Cr

TTK Healthcare Ltd is a standalone TTK Group company in consumer /OTC brands, animal health, medical devices, condoms/sexual-wellness and ready-to-fry foods. Human Pharma was divested in May 2022; agreements to sell EVA and Good Home were signed in July 2026.[1][2]

Potential multibaggers · Q2 FY27

This quarter's potential multibaggers
on management's own guidance

  1. Strong growth
    2
  2. Strong growth
    1
  3. Strong growth
    3
See all potential multibaggersWhere does TTK Healthcare rank?

Portfolio builder

Build your portfolio
from the top-ranked stocks

  1. 1. Pick 3–15 stocks
  2. 2. Choose large, mid or small cap and your sectors
  3. 3. Get a portfolio built from the rankings
Build my portfolio

Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.

Financials of TTK Healthcare

Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.

Shareholder Pattern

TTK Healthcare

Shareholding breakup across reporting periods.

Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
Promoters +74.57%74.57%74.57%74.57%74.57%74.57%74.57%74.57%74.57%74.57%74.57%74.57%
FIIs +1.85%1.85%1.87%1.90%1.90%1.90%1.89%1.90%1.89%1.90%1.86%1.95%
DIIs +3.13%1.14%1.14%1.14%1.14%1.14%1.18%1.18%1.08%1.11%2.19%0.11%
Public +20.46%22.45%22.44%22.39%22.39%22.40%22.37%22.37%22.46%22.43%21.39%23.37%
No. of Shareholders16,65117,22116,93015,76215,78015,89916,11216,13422,48123,68622,80923,993

Financials of TTK Healthcare

Quarterly Results

Quarter-by-quarter operating performance

Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
Sales +186184181208198205190226204209218258233
Expenses +176179169201190197178224198202207243230
Operating Profit105127881235711154
OPM %5%2.9%7%3.3%4.2%3.8%6%1.2%2.6%3.4%5%6%1.6%
Other Income +161616371818131819102117267
Interest1011111111111
Depreciation3332222222222
Profit before tax221824412323221821143029268
Tax %26%27%25%23%26%26%26%26%4%25%26%26%17%
Net Profit +161318321717161320112221223
EPS in Rs11.339.1212.9322.3512.1711.8411.439.2014.437.4515.4015.06157.80

Financials of TTK Healthcare

Profit & Loss

Annual income statement trend

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales +483519528578628646476599725753801857918
Expenses +453478489535578617457577694715767831882
Operating Profit30403843502819223137352637
OPM %6%8%7%7%8%4.4%4.1%3.6%4.3%5.0%4.3%3.0%4.0%
Other Income +7668892842643638568315
Interest4335332353332
Depreciation671215151413131313899
Profit before tax26362930391932486578410883340
Tax %39%36%36%40%38%37%-44%13%3%25%25%20%
Net Profit +1623191824124642640638266277
EPS in Rs20.8129.1924.1312.8617.258.7232.8729.43452.7244.4757.7946.48195.71
Dividend Payout %22%17%21%39%29%34%18%34%2%22%17%22%

Financials of TTK Healthcare

Balance Sheet

Capital structure and asset base

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Sep 2026
Equity Capital88814141414141414141414
Reserves1101281502192372352813169399871,0511,1011,332
Borrowings +42382347293019222723242428
Other Liabilities +115128104127136152180207189183192190276
Total Liabilities2753032854074164314945591,1701,2061,2811,3291,651
Fixed Assets +5210699110988985807175817370
CWIP46101290031015
Investments010991391315131311912
Other Assets +1771851772883043253954631,0831,1181,1891,2461,564
Total Assets2753032854074164314945591,1701,2061,2811,3291,651

Financials of TTK Healthcare

Cash Flows

Operating, investing and financing cash movement

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity +3937182517209645-25-5-4-21
Cash from Investing Activity +-49-275-2210-13-77-3032282052
Cash from Financing Activity +3-11-23-7-31-10-17-10-12-22-18-18
Net Cash Flow-7-00-4-4-425-62-213
Free Cash Flow-102112211389542-36-156-25
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit176%122%67%84%62%108%391%248%-28%54%68%-31%

Financials of TTK Healthcare

Ratios

Working capital efficiency and return ratios

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days343324354743463346424147
Inventory Days62666580771011231028910510798
Days Payable505310013010112117013411611010683
Cash Conversion Cycle4646-11-162223-2119364363
Working Capital Days-31-38-24-30-6-3-32-2844948161
ROCE %20%23%18%15%15%8%6%8%10%9%9%8%
21out of 100

Momentum score · price trend

21 out of 100 — Cooling

Over the past year its share price has done worse than most of the stocks we track.

PeriodShare price changeBetter than … of 1,910 stocks
Last 12 months−22.4%32%
Last 6 months−1.6%52%
Last 3 months−12.9%37%

The price is 47.5% below its all-time high of ₹1,740.05 (13 Sept 2024). Stocks more than 20% below their peak have their score halved, so 41 became 21.

How we calculate it

“Better than 30%” means that over that period the share price did better than 30 out of every 100 stocks we track (1,910 Indian companies worth ₹500 Cr or more, with at least a year of prices).

The score weighs the longer periods more: 40% × 12-month + 40% × 6-month + 20% × 3-month. For TTK Healthcare: 0.4 × 32 + 0.4 × 52 + 0.2 × 37 = 41, halved to 21 because the price is more than 20% below its all-time high.

Strengthening is 70 and above, Steady 40 to 70, Cooling below 40. Scores are recalculated every night after the market closes.

Full methodology →

This describes only how the share price has moved up to 2 Nov 2026, compared with other stocks. It says nothing about the business, and it is not a prediction, a price target or a recommendation to buy or sell.

Continue your research

Others in Diversified this season

  • DCM Shriram Ltd (Q2 FY27)

    Investment in a 40 MW (peak) solar energy plant in Kota at a cost of INR 145 crores to optimize cost management and carbon intensity. Key concall takeaways…

  • Godrej Industries Ltd (Q4 FY25)

    Q4 FY 2024-25 Total Income (Consolidated): ₹6,400 crore, up 25% YoY from ₹5,103 crore (Page 6). Key concall takeaways from Godrej Industries Ltd's Q4 FY25…

  • Godrej Industries Ltd (Q1 FY26)

    Consolidated Total Income: ₹5,719 crore in Q1 FY26, up 9% YoY from ₹5,259 crore in Q1 FY25. Key concall takeaways from Godrej Industries Ltd's Q1 FY26 earnings…

  • Godrej Industries Ltd (Q2 FY26)

    Consolidated Total Income:** ₹6,290 crore, up 23% YoY (Page 6) . Key concall takeaways from Godrej Industries Ltd's Q2 FY26 earnings call — and how it ranks…

Compare:vs 3M India Ltdvs Godrej Industries Ltdvs DCM Shriram Ltd